Lawrence A. Leiter, MD

Lawrence Leiter, MD, FRCP(C), FACP
 

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario
Canada



What specific strategies are currently in the T2D pharmacologic toolkit that have been shown effective for reducing PPG? Where do GLP-1 RAs fit into this scheme?

What specific strategies are currently in the T2D pharmacologic toolkit that have been shown effective for reducing PPG? Where do GLP-1 RAs fit into this scheme?

Are there head-to-head comparisons looking at the effects of different GLP-1 RAs on PPG control? What are the results and implications of those studies?

Are there head-to-head comparisons looking at the effects of different GLP-1 RAs on PPG control? What are the results and implications of those studies?

How do we define PPG? How do we confirm its presence as an actionable metabolic derangement in need of intervention? And where does iGlarLixi fit into this treatment algorithm for PPG?

How do we define PPG? How do we confirm its presence as an actionable metabolic derangement in need of intervention? And where does iGlarLixi fit into this treatment algorithm for PPG?